Carlos Brites

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 507 citations · Full text

Treatment And Prevention, Week 48, Antiviral Drug Development +7

EBV MicroRNAs in Primary Lymphomas and Targeting of <i>CXCL-11</i> by ebv-mir-BHRF1-3

Tianli Xia, Andrea O’Hara, Iguaracyra Araújo et al. · Cancer Research · 2008 · 299 citations · Full text

Nosocomial Bloodstream Infections in Brazilian Hospitals: Analysis of 2,563 Cases from a Prospective Nationwide Surveillance Study

Alexandre R. Marra, Luís Fernando Aranha Camargo, Antônio Carlos Campos Pignatari et al. · Journal of Clinical Microbiology · 2011 · 267 citations · Full text

Pathogenic Microbiology, Brazilian Hospitals, Klebsiella Pneumoniae +13

High Zika Virus Seroprevalence in Salvador, Northeastern Brazil Limits the Potential for Further Outbreaks

Eduardo Martins Netto, Andrés Moreira‐Soto, Célia Pedroso et al. · mBio · 2017 · 221 citations · Full text

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Michael Aboud, Richard Kaplan, Johannes Lombaard et al. · The Lancet Infectious Diseases · 2019 · 190 citations

First-line Therapy, Human Retrovirus, Immunology +9